FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average	ge burden
hours por rospor	neo: 0 F

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* ALTOMARI ALFRED (Last) (First) (Middle) 101 POOR FARM ROAD					2. Issuer Name and Ticker or Trading Symbol <u>AGILE THERAPEUTICS INC</u> [AGRX] 3. Date of Earliest Transaction (Month/Day/Year) 01/29/2019						(Che	elationship of Reporting Person(s) to Issuer ck all applicable) X Director 10% Owner X Officer (give title below) below) Chief Executive Officer			
(Street) PRINCE (City)	TON N	J state)	08540 (Zip) ble I - Non-D		4. If Amendment, Date of Original Filed (Month/Day/Year) ative Securities Acquired, Disposed of, or Be					Line	X Form filed by One Reporting Person Form filed by More than One Reporting Person				
Date				action 2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Ins	on Dispose	ecurities Acquired (A) or ODD		Securities Form		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion Date (Month/Day/Year Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported	Ownersl Form: Direct (I or Indire (I) (Instr.	Beneficial Ownership ct (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)	n(s)	
Employee Stock Option (Right to Buy)	\$0.84	01/29/2019		A		540,900		(1)	01/28/2029	Common Stock	540,900	\$0	540,900) D	
Employee Stock Option (Right to Buy)	\$2.5	01/29/2019		A		154,400		(1)	01/28/2029	Common Stock	154,400	\$0	154,400) D	

Explanation of Responses:

1. This option was granted on January 29, 2019. 25% of the shares subject to the stock option vest on January 29, 2020, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on January 29, 2023.

/s/ Scott M. Coiante, Attorney-

in-Fact

** Signature of Reporting Person

Date

01/31/2019

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.